IRWD News and Press, Ironwood Pharmaceuticals Inc. From 02/29/24

A look at the top 10 most actives in the United States Enveric Biosciences Inc. (ENVB) rose 107.0% to $1.72 on volume of 171,648,007 shares Canoo Inc. (GOEV) rose 0.4% to $0.1055 on volume of 125,030,788 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 6.6% to $3.8476 on vol...

– Apraglutide met the primary endpoint of relative change from baseline in actual weekly parenteral support (PS) volume at week 24, driven by both stoma and colon-in-continuity populations – – Apraglutide also showed a clinically meaningful improvement at week 24, wit...

– Apraglutide nutritional data from STARS Nutrition Phase 2 study in adult patients who have short bowel syndrome with intestinal failure and colon-in-continuity will be highlighted in an oral presentation – – Additional data on apraglutide from previously completed P...

2024-02-15 12:17:02 ET Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2023 Earnings Call Transcript February 15, 2024 08:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Offi...

2024-02-15 07:13:38 ET More on Ironwood Pharmaceuticals Ironwood Pharmaceuticals: Capitalizing On GI Healthcare's Growing Potential Ironwood Pharmaceuticals expects 2024 revenue to be below consensus Seeking Alpha’s Quant Rating on Ironwood Pharmaceuticals ...

– LINZESS ® (Iinaclotide) 2023 U.S. net sales of $1.1 billion, an increase of 7% year-over-year, driven by EUTRx prescription demand growth of 10% year-over-year – – 2023 Ironwood revenue of $443 million, driven primarily by $430 million in U.S. LINZESS colla...

Propanc Biopharma Inc (PPCB) is expected to report for Q2 2024 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 Arch Resources Inc. Class A (ARCH) is expected to report $6.9 for Q4 2023 Bloom Energy Corporation Class A (BE) is expected to report $-0.0...

2024-02-14 14:13:51 ET More on Ironwood Pharmaceuticals Ironwood Pharmaceuticals: Capitalizing On GI Healthcare's Growing Potential Ironwood Pharmaceuticals expects 2024 revenue to be below consensus Seeking Alpha’s Quant Rating on Ironwood Pharmaceuticals ...

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2023 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 15, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (...

2024-01-31 13:59:32 ET Summary Ironwood Pharmaceuticals has established itself as a leader in the gastrointestinal healthcare space with its innovative products and pipeline development. The demand for LINZESS, a therapy for irritable bowel syndrome, is increasing, contributing to...